NEKTAR THERAPEUTICS (NKTR)
2025-06-30 | 2024-09-30 | |||
|---|---|---|---|---|
| Total revenue | 11,175 | 24,124 | ||
| Restructuring and impairment | 447 | 46 | ||
| Research and development (including 613 and 0 for the three months ended june 30, 2025 and 2024, respectively, from a related party and 821 and 0 for the six months ended june 30, 2025 and 2024, respectively, from a related party) | 29,886 | 35,031 | ||
| General and administrative | 17,072 | 18,957 | ||
| Cost of goods sold | - | 4,435 | ||
| Total operating costs and expenses | 47,405 | 58,469 | ||
| Loss from operations | -36,230 | -34,345 | ||
| Other income (expense), net (including income of 540 and 0 for the three months ended june 30, 2025 and 2024, respectively, from a related party and income of 861 and 0 for the six months ended june 30, 2025 and 2024, respectively, from a related party) | 260 | -120 | ||
| Interest income | 1,969 | 3,437 | ||
| Non-cash interest expense on liabilities related to the sales of future royalties | 5,394 | 6,020 | ||
| Total non-operating income (expense), net | -3,165 | -2,703 | ||
| Loss before provision (benefit) for income taxes and equity method investment | -39,395 | - | ||
| Provision (benefit) for income taxes | -188 | 9 | ||
| Loss before equity method investment | -39,207 | - | ||
| Loss from equity method investment | -2,386 | - | ||
| Loss before provision for income taxes | - | -37,048 | ||
| Net loss | -41,593 | -37,057 | ||
| Earnings per share, basic, total | -2.95 | -0.18 | ||
| Earnings per share, diluted, total | -2.95 | -0.18 | ||
| Weighted average number of shares outstanding, basic, total | 14,087,307 | 209,249,000 | ||
| Weighted average number of shares outstanding, diluted, total | 14,087,307 | 209,249,000 | ||